---
title: 'Executive Director, Payer Strategy and Engagement (Tumor HI Program) at Rezolute'
canonical: 'https://feeny.ai/job/executive-director-payer-strategy-and-engagement-tumor-hi-program-rezolute-wwhsbrjyytpa'
type: 'job'
last_seen: '2026-11-06'
---

# Executive Director, Payer Strategy and Engagement (Tumor HI Program) at Rezolute

- **Company:** Rezolute
- **Location:** Redwood City, CA
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-06-02
- **Last confirmed live:** 2026-11-06
- **Apply:** https://jobs.lever.co/rezolutebio/d96188b9-ab6e-4389-8358-ee102dac9da2

## Job description

Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation, collaboration, and integrity. Rezolute’s lead investigational therapy, RZ358 (ersodetug), is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI). As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI), most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH), the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders.

## POSITION SUMMARY

- Provide critical leadership and above-country market access strategies including core disease models, value stories, global pricing, economic modeling, and input into Clinical Development programs.
- Work closely with Medical Affairs colleagues, Organized customers and Distribution providers to identify real-world and patient quality of life data capture / evidence value solutions and publication opportunities.
- Monitors healthcare legislative trends, understands healthcare policies, assesses implications of policies, and develops reimbursement strategies that address barriers to provider and patient access.
- Understands total cost of care and all aspects of reimbursement (coverage, coding, and payment) for outpatient and inpatient settings across multiple payer segments.
- Support the formulation of a clear and compelling disease and product value propositions through the creation of payer engagement (AMCP Dossier, Value and Economic Prop.), and provider / patient reimbursement support tools.
- Monitor the competition to understand how the evolving market will impact current and future market access strategies.
- Identify and develop pricing recommendations, coding and reimbursement strategies for current and pipeline assets that will support future Pricing and Reimbursement decisions in the US and other key Ex-US markets.
- Engage to support the advancement of ICD-10 CM coding initiatives, and product-specific HCPCS coding application.
- Identify product market access risks and opportunities, incorporate them into pipeline product strategies and reflect them in identified Target Product Profiles.
- Identify pricing and reimbursement analogues to support value and access decisions.
- Create payer materials for branded and unbranded disease awareness campaigns.
- Support the identification, creation of defensible, performance driven, quality / outcomes or risked based product / portfolio contract, or rebate opportunities.
- Manage agency relationships and contracts to deliver tools/tactics/resources, and ensure on time delivery, that is aligned with the departmental budget.
- Provide subject matter expertise to the broader organization, including competitive and product coverage access intelligence, healthcare reform, landscape trends, and pull-through initiatives.  This includes cross-functional support of corp. training initiatives, content, tools and presentation development in partnership with Training and Cross-Departmental leaders.
- Represent Rezolute at Key Industry Conferences (e.g. AMCP, PCMA, ISPOR, Asembia, etc.).
- Ensure that all activities and interactions are carried out with the highest ethical and professional standards, and that all work is accomplished with quality and in accordance with Rezolute values.
- Manage/recruit in-house or contracted payer account team to educate key payers using PIE (Payer Information Exchange) before approval and PVP (Payer Value Proposal) after the approval
- Educate payers on the label and influence them to develop policies based on the label and/or clinical trial exclusion criteria
- Resolve rejection/prior authorization issues by closely working with the payers and patients support services team and hub in a timely manner

## QUALIFICATIONS

- Experience with rare/orphan drugs is required. Therapeutic area experience is a plus.
- Product launch experience is required, and company start-up experience is preferred.
- Familiarity with current legal and regulatory landscape pertinent to the pharmaceutical/biotechnology industry.
- Strong analytical capabilities, with working knowledge of government pricing practices (calculations methodologies, HTA, healthcare programs, and supporting regulations), and trade systems and processes.
- Demonstrated flexibility to adapt to a changing environment, implement creative solutions to complex problems, and ability to function in a project leadership role.
- Ability to develop and maintain strong internal and external relationships, including direct collaboration with vendors and other third parties.
- Superior interpersonal, oral and written communication, and presentation skills, with great attention to detail.
- Leads with strong business acumen and a compliance mindset.
- Passionate about patients and building a new commercial organization.
- Advanced Microsoft Excel, Word and PowerPoint skills.

PREFERRED EXPERIENCE, EDUCATION, CERTIFICATIONS, LICENSES:

- Minimum Bachelor’s degree required; sciences or business preferred, advanced degree related medical, health economics, health outcomes research, or epidemiology (MS, MBA, MPH, MD/DO, PhD, PharmD) preferred.
- Minimum of 10 years of overall industry experience in biotech or pharmaceuticals (i.e. market access and reimbursement, sales, sales management, marketing, training, sales operations, or healthcare / life sciences consulting).
- 5 years of US market access and reimbursement experience required, with Global and/or international experience preferred.  This includes, HTA, US Payer, Patient and Provider access, HEOR, and medical benefit reimbursement coding expertise.

Rezolute (RZLT) currently anticipates the base salary for the Executive Director, Payer Strategy and Engagement role could range from $290,000 to $320,000 and will depend, in part, on the successful candidate’s geographical location and their qualifications for the role, including education and experience. This position will also be eligible for an annual performance bonus in accordance with the terms of the applicable plan (depending, in part, on company and individual performance and at the Company’s discretion on an individual basis). The compensation described above is subject to change and could be higher or lower than the range described based on current market survey data and the qualifications, education, experience and geographical location of the selected candidate.

This role is based in the home office and requires minimum of 3 days per week in the office.

Qualifying employees are eligible to participate in benefit programs such as:

Health Insurance (Medical / Dental / Vision) Disability, Life & Long-Term Care Insurance Holiday Pay Tracking Free Vacation Program 401(k) Plan Match Educational Assistance Benefit Fitness Center Reimbursement

We are an Equal Opportunity Employer and do not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class.

## About Rezolute

## Company Overview
- **One-liner**: Rezolute is a late-stage rare disease biotechnology company developing ersodetug, a monoclonal antibody therapy for hypoglycemia caused by congenital and tumor hyperinsulinism.
- **Entity Type**: Public (Nasdaq: RZLT)
- **Headquarters**: Redwood City, California, United States (with an additional office in Louisville)
- **Founded**: Not publicly available (IPO 2012)
- **Founders**: Not publicly available

## Core Business
- **Primary industry**: Biotechnology – rare disease therapeutics
- **Target customers**: B2B – healthcare providers, patients, and payers; focuses on addressing severe unmet medical needs in hyperinsulinism
- **Mission/purpose**: Significantly improve outcomes for individuals with hypoglycemia caused by hyperinsulinism ([rezolutebio.com – About](https://rezolutebio.com/job-openings/))

## Products & Services
- **Ersodetug (lead candidate)**: An intravenously administered human monoclonal antibody that allosterically binds to the insulin receptor, down‑modulating insulin action to restore normal glucose levels. Being developed for two indications:
  - **Congenital Hyperinsulinism (sunRIZE Phase 3 study)** – completed enrollment (May 2025) with 62 participants; topline results expected December 2025.
  - **Tumor Hyperinsulinism (upLIFT Phase 3 study)** – initiated mid‑2025; FDA agreed to a single‑arm open‑label design; topline results expected second half 2026.
  - Designations: Orphan Drug (US/EU), Rare Pediatric Disease, Breakthrough Therapy (US), PRIME (EU), ILAP (UK) ([ir.rezolutebio.com – 10-K](https://ir.rezolutebio.com/sec-filings/content/0001104659-25-090848/0001104659-25-090848.pdf))

## Market Standing
- **Valuation/Market Cap**: $317.7 million (as of recent data, per LinkedIn) ([linkedin.com](https://linkedin.com/company/rezolute))
- **Key Metric (Public)**: Annual revenue of $14.1 million (likely from grants or collaboration revenue; no product revenue yet) ([linkedin.com](https://linkedin.com/company/rezolute))
- **Notable Investors/Partners**: Not publicly available – company is publicly traded and does not disclose a lead investor list. Key partners include clinical trial sites and regulatory agencies (FDA, EMA).
- **Growth Signals**:
  - Headcount: 50 employees (+2.9% YoY) ([linkedin.com](https://linkedin.com/company/rezolute))
  - Phase 3 sunRIZE study fully enrolled; topline data pending December 2025.
  - Phase 3 upLIFT study enrolling with streamlined design; data expected second half 2026.
  - FDA granted Breakthrough Therapy Designation for tumor HI in May 2025.
  - Multiple regulatory designations accelerating development pathway.

## Competitive Advantages
- **Unique mechanism**: Ersodetug acts downstream from beta cells at the insulin receptor, allowing it to potentially treat all forms of hyperinsulinism (genetic or acquired) regardless of underlying cause.
- **Dosing convenience**: Half‑life >2 weeks enables monthly intravenous administration.
- **Regulatory momentum**: Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, PRIME, and ILAP designations provide expedited review, potential priority review voucher, and closer FDA/EMA collaboration.
- **Pivotal data catalysts**: Two Phase 3 studies read out within ~12‑18 months, creating clear value inflection points.

## Strategic Focus
- Execute the two ongoing Phase 3 trials (sunRIZE in congenital HI, upLIFT in tumor HI).
- Assuming positive topline data from sunRIZE, submit a Biologics License Application (BLA) to the FDA for ersodetug in mid‑2026.
- Continue to build commercial and medical affairs infrastructure (recent job postings indicate hires in Commercial Operations, Marketing, Payer Strategy, and Supply Chain) ([rezolutebio.com – Job Openings](https://rezolutebio.com/job-openings/)).

## Why Work Here
- **Mission‑driven**: Employees work on therapies for ultra‑rare, life‑threatening conditions with high unmet medical need.
- **Benefits**: Comprehensive health/dental/vision insurance, competitive salaries, annual bonus, 401(k) with company match, tuition assistance, on‑site meals, flexible spending accounts ([rezolutebio.com – Benefits](https://rezolutebio.com/job-openings/)).
- **Work environment**: Hybrid/office policy not explicitly stated; roles are based in Redwood City (HQ) and Louisville. Recent openings include remote-friendly functions? Not confirmed.
- **Growth opportunity**: Small company (~50 people) entering late‑stage development and pre‑commercial build‑out – employees can have broad impact and career advancement.
- **Engineering culture**: For biotech, the focus is on clinical operations, regulatory, and commercial roles rather than traditional engineering. IT positions (Business System Engineer) exist.

## Sources
1. [linkedin.com – Rezolute company page](https://linkedin.com/company/rezolute)
2. [rezolutebio.com – Job Openings & Benefits](https://rezolutebio.com/job-openings/)
3. [ir.rezolutebio.com – SEC 10-K Filing (September 2025)](https://ir.rezolutebio.com/sec-filings/content/0001104659-25-090848/0001104659-25-090848.pdf)
4. [rezolutebio.com – Leadership page](https://rezolutebio.com/leadership/)

## Other roles at Rezolute

- [Director – Biostatistics](https://feeny.ai/job/director-biostatistics-rezolute-redwood-city-rsdg74z82vkk) — Redwood City, CA
- [Medical Science Liaison / Senior Medical Science Liaison - Oncology / Rare Endocrine Disorders](https://feeny.ai/job/medical-science-liaison-senior-medical-science-liaison-oncology-rare-endocrine-bhs2782j7gtm)
- [Medical Science Liaison / Senior Medical Science Liaison - Pediatric Endocrinology / Rare Metabolic Disorders](https://feeny.ai/job/medical-science-liaison-senior-medical-science-liaison-pediatric-endocrinology-pvkvqb4szfae)
- [Recruiting Coordinator & Scheduler – 6 month contract](https://feeny.ai/job/recruiting-coordinator-scheduler-6-month-contract-rezolute-redwood-city-x0gcanx9q7vf) — Redwood City, CA
- [Contract Recruiter (Biopharmaceutical Industry) 6 month contract](https://feeny.ai/job/contract-recruiter-biopharmaceutical-industry-6-month-contract-rezolute-redwood-jvpc3bn5g8t2) — Redwood City, CA
- [Senior Manager, Scientific Communications & Medical Education](https://feeny.ai/job/senior-manager-scientific-communications-medical-education-rezolute-redwood-city-363wemxkxap1) — Redwood City, CA
- [Head of Product Launch Program Management (Rare Disease)](https://feeny.ai/job/head-of-product-launch-program-management-rare-disease-rezolute-redwood-city-7qka6sahvk1h) — Redwood City, CA
- [Associate Director, Medical Affairs Operations](https://feeny.ai/job/associate-director-medical-affairs-operations-rezolute-redwood-city-gg2p7j75sszn) — Redwood City, CA
- [Vice President, Global Manufacturing](https://feeny.ai/job/vice-president-global-manufacturing-rezolute-redwood-city-wcyqhfyet1yw) — Redwood City, CA
- [Vice President, Global Supply Chain](https://feeny.ai/job/vice-president-global-supply-chain-rezolute-redwood-city-q0dngx787mdk) — Redwood City, CA